IgA nephropathy

News

Travere weaker after Filspari fails confirmatory trial

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspar

News

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

Further evidence of big pharma’s return to M&A dealmaking in 2023 has come this morning from Novartis, which has just agreed a takeover of rival Chinook Therapeutics f

News

Travere undercuts key rival in rare kidney disease IgAN

Filspari will launch for IgA Nepropathy at a discount to Calliditas' Tarpeyo, cleared in 2021.

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Calliditas hits $90m jackpot as biotech IPO craze continues

Swedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease specialist at $467 million as the craze for biotech I

Travere weaker after Filspari fails confirmatory trial

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

Travere undercuts key rival in rare kidney disease IgAN

Calliditas hits $90m jackpot as biotech IPO craze continues

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

IgA nephropathy

Editor's Picks